Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.12.7345

Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?  

Abdelgawad, Iman Attia (Department of Clinical and Chemical Pathology, NCI, Cairo University)
Mossallam, Ghada Ibrahim (Department of Clinical and Chemical Pathology, NCI, Cairo University)
Radwan, Noha Hassan (Department of Clinical and Chemical Pathology, NCI, Cairo University)
Elzawahry, Heba Mohammed (Department of Medical Oncology, NCI, Cairo University)
Elhifnawy, Niveen Mostafa (Department of Clinical and Chemical Pathology, NCI, Cairo University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.12, 2013 , pp. 7345-7349 More about this Journal
Abstract
Background: Because of the high prevalence of hepatocellular carcinoma (HCC) in Egypt, new markers with better diagnostic performance than alpha-feto protein (AFP) are needed to help in early diagnosis. The aim of this work was to compare the clinical utility of both serum and mRNA glypican3 (GPC3) as probable diagnostic markers for HCC among Egyptian patients. Materials and Methods: A total of 60 subjects, including 40 with HCC, 10 with cirrhosis and 10 normal controls were analyzed for serum GPC3 (sGPC3) by ELISA. GPC-3 mRNA from circulating peripheral blood mononuclear cells was amplified by RT-PCR. Both markers were compared to some prognostic factors of HCC, and sensitivity of both techniques was compared. Results: Serum glypican-3 and AFP were significantly higher in the HCC group compared to cirrhotic and normal controls (p<0.001). Sensitivity and specificity were (95% each) for sGlypican-3, (82.5% and 85%) for AFP, and (100% and 90%) for Glypican3 mRNA, and (80% and 95%) for double combination between sGPC3 and AFP respectively. Conclusion: Both serum GPC-3 and GPC-3mRNA are promising diagnostic markers for early detection of HCC in Egyptian patients. RT- PCR proved to be more sensitive (100%) than ELISA (95%) in detecting glypican3.
Keywords
Glypican3; ELISA; RT/PCR; HCC; diagnosis; Egypt;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gomaa A, Hendy O, Aboraia G, et al (2012). The diagnostic Value of Peripheral blood Glypican-3 in patients with hepatocellular carcinoma. World J Med Sci, 7, 105-12.
2 Hippo Y, Watanabe K, Watanabe A, et al (2004). Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res, 64, 2418-23.   DOI   ScienceOn
3 Iglesias V, Centeno G, Pascucceli H, et al (2008). Expression pattern of glypican-3 (GPC-3) during human embryonic and fetal development. Histol Histopathol, 23, 1333-40.
4 Inoue K, Sugiyama H, Ogawa H, et al (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 3071-9.
5 Jackbovic B, Jothy S (2007). Glypican-3 from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol, 82, 184-9.   DOI   ScienceOn
6 Kandil D, Cooper K (2009). Glypican-3: A novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 16, 125-9.   DOI   ScienceOn
7 Lehman EM, Wilson ML (2009). Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systemic review and meta-analysis. Int J Cancer, 124, 690-7   DOI   ScienceOn
8 Li BD, Zhao QC, Zhu YT, et al (2006). Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi, 44, 458-62.
9 Liu H, Li P, Zhai Y, et al (2010). Diagnostic value of Glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol, 16, 4410-5.   DOI
10 Trerotoli P, Fransvea E, Angelotti U et al (2009).Tissue expression of squamous cellular carcinoma antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 8, 29.   DOI   ScienceOn
11 Yan D, He Q, Chen Y, et al (2011). Detection of $\alpha$-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal, 25, 113-7.   DOI   ScienceOn
12 Yasuda E, Kumada T, Toyoda H, et al (2010). Evaluation for clinical utility of GPC-3, measured by a commericially available ELISA kit with GPC-3 antibody, as a serological and histological marker for HCC. Hepatol Res, 40, 477-85.   DOI   ScienceOn
13 Youssef M, El-Sharkawy S, Abbas N, et al (2010). Clinical utility of Glypican-3 in hepatocellular carcinoma. Int J Integr Biol, 10, 41-7.
14 Zakhary N, Khodeer S, Ezzat H, et al (2012). Impact of PIVKAII in diagnosis of hepatocellular carcinoma. International Conference on Ecological Environmental and Biology Sciences, ICEEBS, Jan. 7-8 Dubai.
15 National Cancer Institute Cairo (2010). Cancer registry 2002-2007. Website: www.nci.edu.eg.data.
16 Anwar WA, Khaled HM, Amra HA, et al (2008). Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res, 659, 176-84.   DOI   ScienceOn
17 El-Shenawy S, El Sabawi M, Sheble N, et al (2012). Diagnotic Role of serum Glypican-3 as a tumor marker for hepatocellular carcinoma. Nature Sci, 10, 32-8.
18 Filmus J, Capurro M (2004). Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diag, 8, 207-12.   DOI
19 Nakatsura T, Nishimura Y (2005). Usefulness of the novel oncofetal antigen, Glypican 3, for diagnosis of hepatocellular carcinoma and melanoma. Bio Drugs, 19, 71-7.
20 Nakatsura T, Yoshitake Y, Senju S, et al (2003). Glypican 3 : Overexpressed specially in human hepatocellular carcinoma., is a novel tumor marker. Biochem Biophys Res Commun, 306, 16-25.   DOI   ScienceOn
21 Nishimura Y, Nakatsura T, Senju S (2008). Usefulness of a novel oncofetal antigen, Glypican 3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi, 31, 383-91.   DOI   ScienceOn
22 Qiao SS, Cui Z, Gong L, et al (2011). Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepato-Gastroenterol, 58, 1718-24.
23 Shafizadeh N, Ferrel P, Karkar S (2008). Utility and limitation of Glypican-3 expression for the of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol, 21, 1011-8.   DOI   ScienceOn
24 Sung YK, Hwang SY, Park MK et al (2003). Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci, 94, 259-62.   DOI   ScienceOn
25 Suriawinata A, Thung SN (2010). Molecular signature of early hepatocellular carcinoma. Oncol, 78, 36-9.   DOI   ScienceOn
26 Tangkijvanich P, Chanmer T, Komtong S, et al (2010). Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol, 25, 129-37.   DOI   ScienceOn